Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. His research focuses on the use of comparative effectiveness research and cost-effectiveness analysis in health care decision making. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care.
Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He is the author or co-author of over 250 papers in the medical literature, the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) and co-editor of Cost-Effectiveness in Health and Medicine, 2nd Edition (Oxford University Press, 2017).
He is a member of the editorial advisory boards of Health Affairs and Value in Health and serves or has served on many advisory boards, including advisory boards for the Congressional Budget Office and the Robert Wood Johnson Foundation.
He received his ScD in Health Policy and Management from Harvard University.
Joshua Cohen, PhD, is the Deputy Director and Chief Science Officer of the Center for the Evaluation of Value and Risk in Health at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, and a Research Professor of Medicine at Tufts School of Medicine. Dr. Cohen’s work focuses on the advent of “drug value frameworks”, with a special focus on the Institute for Clinical and Economic Review (ICER) framework, promotion of "open source" practices for health economic simulation models, and the potential benefits of risk-targeted disease screening.
Dr. Cohen received both his PhD in Decision Sciences and his BA in Applied Mathematics from Harvard University.
James is an investigator at CEVR, and an Associate Professor of Medicine at Tufts University School of Medicine. His research is focused on examining the factors that influence payer coverage of medical technology and quantifying pharmaceutical innovation. He graduated from Queens University in Belfast with an MPharm degree and previously worked as a pharmacist in the UK and Ireland. James also obtained an MSc from the University of York and PhD from Brunel University, both in Health Economics.
Natalia is an investigator at CEVR, and a Research Assistant Professor of Medicine at Tufts University School of Medicine. Her research includes decision modeling and analysis of clinical and economic outcomes, understanding the role of risk and treatment effect heterogeneity analysis in population level decision making, and identifying opportunities for improvement of health system efficiency. She holds a PhD in Clinical and Translational Science from Tufts University, a MS in Operations Research from Columbia University, and an SB from MIT.
Daniel Ollendorf is Director of Value Measurement and Global Health Initiatives at CEVR and Assistant Professor of Medicine at Tufts University School of Medicine. Dr. Ollendorf’s research interests include expanding the use of health technology assessment (HTA) and economic evaluation in low- and middle-income countries, as well as refinement and use of value assessment tools in the US and other high-income settings.
Prior to joining CEVR, he was Chief Scientific Officer for the Institute for Clinical and Economic Review (ICER) for over 10 years, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators. Dr. Ollendorf rejoined ICER in November 2023 as its Chief Scientific Officer and Director of HTA Methods and Engagement, and continues to maintain his CEVR faculty appointment on a part-time basis. He is also a non-resident Fellow in Global Health at the Center for Global Development, and recently completed a 5-year term as Chair of the Health Technology Assessment International (HTAi) Global Policy Forum. He received his PhD in Clinical Epidemiology from the University of Amsterdam, and an MPH in Health Policy & Management/Epidemiology from Boston University.
Tara Lavelle is an assistant professor at the Center for the Evaluation of Value and Risk in Health. Her research measures family-centered outcomes and preferences for health care to inform value assessments and other health care policies. She received her PhD in Health Policy with a concentration in Decision Science from Harvard University in 2012 and was previously a postdoctoral research fellow in the Child Health Evaluation and Research Unit in the Division of General Pediatrics at the University of Michigan.
Paige is an investigator at CEVR, and an Associate Professor of Medicine at Tufts University School of Medicine. Her research focuses on health and economic outcomes of individuals with chronic conditions such as Alzheimer’s disease, cancer and diabetes. Paige received her PhD in Health Policy and Management from the University of North Carolina at Chapel Hill and her Masters in Health Policy and Management from the Harvard School of Public Health.
Dr. Li received her ScM in Epidemiology from Johns Hopkins University and her PhD in Pharmaceutical Outcomes Research & Policy from University of Washington. She completed a two-year postdoctoral fellowship at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. Her research interests include defining and measuring novel elements of value for medical technologies, pharmaceutical pricing, and evaluating the impact of new drug innovations on population health and equity.
Jon (Jonathan D.) Campbell is Senior Vice President for Health Economics at the Institute for Clinical and Economic Review (ICER). Jon joined ICER’s senior management team as a leader in value assessment methods and application; he oversees the growth of ICER’s health economics efforts and leads the continued innovation of ICER’s value assessment methodology. Additionally, Jon continues to build bridges within the global health economics community through engagement with ICER’s Health Economic Council and through leadership and participation in health technology assessment societies and agencies. Further, Jon seeks creative value assessment solutions for ICER’s diverse stakeholders by prioritizing improved outcomes for patients.
Jon is an author of over 100 peer-reviewed manuscripts in the field of value assessment as well as ten ICER topics. Jon was an ICER Health Economics Council member and five-year external collaborator through his former role as Associate Professor with tenure at the University of Colorado Anschutz Medical Campus. Jon likes to work with numbers and with teams to solve problems. He holds graduate training degrees in pharmaceutical outcomes research (PhD) and biostatistics (MS) from the University of Washington and a BA in mathematics and chemistry from St. Olaf College.
David is an investigator at CEVR, and an Assistant Professor of Medicine at Tufts University School of Medicine. His research focuses on using clinical and economic evidence in health policy, evaluating the economic value of health/nutrition policy and medical technology, and improving research prioritization using a value of information approach. He received his doctorate in Health Services (Health Economics) from University of Washington
Molly is Project Director of the Specialty Drug Evidence and Coverage (SPEC) database team. Her research focuses on the impact of US health plan coverage decisions on patients’ access to treatment. Prior to joining CEVR, Molly served as Senior Research Lead at the Institute for Clinical and Economic Review (ICER). Molly holds a dual BA in Biology and Psychology from Cornell University and an MPH from Boston University School of Public Health.
Katie is a research assistant on the Specialty Drug Evidence and Coverage (SPEC) database. She graduated from Franklin and Marshall College in 2021 with a BA in Public Health Biology and is currently pursuing an MPH in Epidemiology and Biostatistics from Boston University School of Public Health
Elliott's research focuses on uncertainty in health technology assessments and supporting the CEA Registry. She received an MA in Economics and a BS in Quantitative Economics from Miami University of Ohio.
Daniel manages the Specialty Drug Evidence and Coverage (SPEC) Database. His research examines how US health plans cover specialty drugs, with a focus on health plans' consideration of cost-effectiveness and health technology assessments in their coverage decisions. Daniel holds a BA in Economics from the University of Vermont and a MS in Applied Pharmacoeconomics from the University of Florida's College of Pharmacy.
Kristen is the Business Development and Communications Manager for the Center for the Evaluation of Value and Risk in Health. Her role consists of research and project assistance as well as logistical support for multiple meetings, seminars, conferences and staff travel. Kristen received her BS at Anna Maria College and has over six years of professional experience in the healthcare industry.
Fariel is a research assistant on the Specialty Drug Evidence and Coverage (SPEC). She graduated from Colby College in 2022 with a BA in Economics and Science, Technology, and Society (STS).
Adele is a researcher on the Specialty Drug Evidence and Coverage (SPEC) database team. Their research focuses on the impact of US health plan coverage decisions on patients’ access to treatment. Adele holds a BA in Health in Human Biology from Brown University and an MPH from Boston University School of Public Health. They are currently pursuing their PhD in Health Services Research at the Boston University School of Public Health.
Lichen joined CEVR as a statistician/data scientist. He is passionate about using data for social good. He graduated from the University of Minnesota with a PhD in Electrical and Computer Engineering, specializing in applying machine learning to medical imaging.
Ching’s favorite part in health decision science is bridging the gap between science and health policy. At CEVR, he aspires to go beyond being a physician and improve patients’ health at a population level through cost-effectiveness analysis and modeling research.
Before joining CEVR, Ching practiced at Linkou Chang Gung Memorial Hospital. He earned an MD degree from Chung Shan Medical University in Taiwan and then pursued a master’s degree in Health Policy at Harvard T.H. Chan School of Public Health.
Sarah is the Research Project Coordinator for the Center for the Evaluation of Value and Risk in Health. Her role consists of scheduling meetings, seminars, and assisting CEVR staff with administrative duties. She graduated from Kansas State University in 2021 with a BS in Human Development and Family Sciences with a minor in Dance.
Ekwu is a pharmacist with a master's degree in HIV&AIDS management from Stellenbosch University, and PhD and master's degrees in Health Policy from Brandeis University Massachusetts. His research interests are in genomic medicine, immunology, cancer therapy, and CNS disorders. At CEVR he is presently on a team researching Genomic Medicine in Neonates and Infants.
Divya is a Research Assistant on the Cost Effectiveness Analysis (CEA) Registry. Her work supports research activities involving health plan coverage of medical technology, health economics, and cost-effectiveness analyses. She holds a Master with Thesis in Pharmaceutical Health Services Research from the University of Maryland, Baltimore, with her thesis titled 'A Cost-Effectiveness Analysis Model Framework for Treatments of Early-Stage Huntington's Disease Patients in the United States.'
Marie is a research assistant who is primarily interested in global health policy and economics. She graduated from the University of Southern California in 2021 with a BA in International Relations and Global Business and a minor in Global Health.
Ellen earned an MD in China and an MPH in epidemiology at University of Michigan at Ann Arbor. She recently received her PhD in Pharmaceutical Outcomes and Policy from the University of North Carolina at Chapel Hill. She is primarily interested in facilitating the decision-making process for diverse stakeholders through observational studies and economic modeling to evaluate the impact of drug utilization on both patient health outcomes and the healthcare system.
Abigail’s work focuses on evaluating uncertainty in health technology assessments and measuring caregiver outcomes to be incorporated into cost-effectiveness analysis. Abigail graduated from Boston College in 2021 with a BA in Economics and History.
Julia’s research focuses on the consistency of restrictions for drug indication pairs between third party payers and their FDA labels. Julia graduated from the University of New Hampshire in 2020 with a BA in Social Work, and is currently pursuing a Masters in Social Work and Public Health at Boston University.
Patty works with the research team to manage, update, and maintain both the Cost-Effectiveness Analysis Registry and the Global Health Cost-Effectiveness Analysis Registry. She also contributes to global health research at CEVR, with a particular focus on economic evaluation in low- and middle-income countries. Prior to joining CEVR, Patty served as Director of Evidence Review at the Institute for Clinical and Economic Review (ICER). Patty received her MS in Applied Food and Nutrition Policy from Tufts University, MA in International Development and Humanitarian Affairs from the Fletcher School of Law and Diplomacy (at Tufts University), and BA in the Humanities from Providence College.
Sean Tunis, MD, MSc. is a Principal with Rubix Health where he consults with public and private sector organizations on health technology issues at the interface of regulatory and reimbursement policy, market access, comparative effectiveness, outcomes measurement and health technology assessment.
He is also Senior Fellow in the Tufts Center for the Evaluation of Value and Risk in Health and serves as a Mentor-in-Residence at Johns Hopkins Tech Ventures, helping early-stage companies align their clinical development programs with payer and regulatory requirements.
In 2020 and 2021, Dr. Tunis served as a Senior Advisor in the Office of the Principal Deputy Commissioner at the Food and Drug Administration, where he worked on the use of real-world data to inform regulatory and reimbursement decisions for medical devices and diagnostics.
Emma is the database coordinator for the Specialty Drug Evidence and Coverage (SPEC) database. She graduated from Tufts University in 2023 with a BA in Community Health and Environmental Studies.
Melanie Whittington is a Senior Fellow at the Center for the Evaluation of Value and Risk in Health (CEVR) where she advises on CEVR projects related to value assessment, economic modeling, and CEVR databases. Her research is dedicated to developing and applying novel methods for value assessment.
She is also the Principal and Founder of Valusphere where she conducts economic analyses, advises on health technology assessment, and provides training to value assessment stakeholders.
Prior to joining CEVR, she was the Director of Health Economics for the Institute for Clinical Economic Review (ICER) where she led the cost-effectiveness analyses and budget impact analyses within ICER reviews. She remains on ICER's Health Economics Council. She is an active member in the International Society for Pharmacoeconomics and Outcomes Research and was the 2022 recipient of the Bernie J. O'Brien New Investigator Award.
Yolanda received her PhD and master’s degrees in Public Policy from the University of Southern California. At CEVR, her research is focused on racial disparities in health care among persons living with dementia as well as reducing low-value care services.
We are a team of dedicated individuals who are passionate about measuring value in healthcare. We offer a unique working environment that values expertise and rewards individual contributions.